Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference

BHVN 01.07.2025

SERA-AI Powered Highlights
Date of Upcoming Event:2025-01-13
Name of Upcoming Event:43rd Annual J.P. Morgan Healthcare Conference
Full Press ReleaseSEC FilingsOur BHVN Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation P
  • 01.13.2025 - Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
  • 01.13.2025 - 42nd Annual J.P. Morgan Healthcare Conference

Recent Filings

    NEW HAVEN, Conn.,Jan. 7, 2025/PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel inSan Francisco, California, onMonday, January 13, 2025, at8:15 am (PT).

    (PRNewsfoto/BIOHAVEN LTD)

    About BiohavenBiohavenis a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology.Biohavenis advancing its innovative portfolio of therapeutics, leveraging its proven drug development experience and multiple proprietary drug development platforms.Biohaven'sextensive clinical and nonclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for OCD and SCA (spinocerebellar ataxia); myostatin inhibition for neuromuscular and metabolic diseases, including SMA and obesity; antibody recruiting bispecific molecules and antibody drug conjugates for cancer. For more information, visitwww.biohaven.com.

    Forward-looking StatementsThis news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes ofBiohaven'splanned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicableU.S.regulatory requirements; the potential commercialization ofBiohaven'sproduct candidates; and the effectiveness and safety ofBiohaven'sproduct candidates. Additional important factors to be considered in connection with forward-looking statements are described inBiohaven'sfilings with theSecurities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this news release, andBiohavendoes not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

    Investor Contact:Jennifer PorcelliVice President, Investor Relationsjennifer.porcelli@biohavenpharma.com+1 (201) 248-0741

    Media Contact:Mike BeyerSam Brown Inc.mikebeyer@sambrown.com+1 (312) 961-2502

    CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/biohaven-to-present-at-the-43rd-annual-jp-morgan-healthcare-conference-302345039.html

    SOURCEBiohaven Ltd.

    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com